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Summary In 29 chemotherapy-naive patients with stage II-III breast cancer, peripheral blood stem cells
(PBSCs) were mobilised following fluorouracil 500mgm-2, epirubicin 90-120mg m2 and cyclophosphamide
500 mg m-2 (FEC) and granulocyte colony-stimulating factor (G-CSF; Filgrastim) 300iLg s.c. daily. In all but
one patient, mobilisation was successful, requiring three or fewer leucocytopheresis sessions in 26 patients; 28
patients subsequently underwent high-dose chemotherapy consisting of carboplatin 1600 mgm-2, thiotepa
480 mg m-2 and cyclophosphamide 6 g m-2 (CTC) followed by PBSC transplantation. Haemopoietic engraft-
ment was rapid with a median time to neutrophils of 500 x 10 1-' of 9 days (range 8-10) in patients who
received G-CSF after PBSC-transplantation; platelet transfusion independence was reached within a median of
10 days (range 7-16). Neutropenic fever occurred in 96% of patients. Gastrointestinal toxicity was substantial
but reversible. Renal, neural or ototoxicity was not observed. Complications related to the central venous
catheter were encountered in 64% of patients, with major vein thrombosis occurring in 18%. High-dose
CTC-chemotherapy with PBSC-transplantation, harvested after mobilisation with FEC and G-CSF, is
reasonably well tolerated without life-threatening toxicity and is a suitable high-dose strategy for the adjuvant
treatment of breast cancer.
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The ability of adjuvant chemotherapy to improve long-term
disease-free and overall survival in patients with breast
cancer and tumour-positive axillary lymph nodes is now
widely recognised (Early Breast Cancer Trialists' Col-
laborative Group, 1992; Olivotto et al., 1994). The precise
characteristics of patient groups that benefit most from this
treatment modality and the optimal type, duration and inten-
sity ofchemotherapy, however, continue to be the subjects of
intensive research (Fisher et al., 1992).
One major approach to further improve the results of
chemotherapy in breast cancer is dose intensification (Ant-
man, 1992a; Wood et al., 1994). Studies with haematological
growth factors such as granulocyte colony-stimulating factor
(G-CSF) and granulocyte-macrophage colony-stimulating
factor (GM-CSF) have shown that the chemotherapy dose
per unit of time can be increased by a factor 1.5-2.0 (as
compared with 'standard' doses) in young patients with
breast cancer (Bronchud et al., 1989; Gianni et al., 1990). At
these dose levels, thrombocytopenia and organ toxicity
become dose-limiting. In non-randomised studies, this type of
intensified chemotherapy typically leads to high response
rates in patients with advanced disease, but not to long-term
survival. Further dose escalation, beyond the levels
achievable with growth factors alone, requires autologous
bone marrow stem cell support. In patients with advanced
disease, high-dose multiple alkylator chemotherapy may lead
to a 17-26% long-term disease-free survival (Livingston,
1994). Subgroup analyses of non-randomised studies suggest
that patients who receive high-dose chemotherapy as con-
solidation treatment in a chemotherapy-induced complete
remission may profit most (Klumpp et al., 1994). The
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preliminary results of a prospective Dutch multicentre study
indicate a similar effect (de Vries et al., 1994).
Recently, a number of studies have investigated the
feasibility of high-dose chemotherapy with autologous bone
marrow support in young patients with high-risk MO breast
cancer (Gianni et al., 1992; Mulder et al., 1993; Peters et al.,
1993). The largest ofthese (Peters et al., 1993) reported on 85
patients, who received four cycles ofcyclophosphamide, dox-
orubicin and fluorouracil, followed by a high-dose
chemotherapy regimen incorporating cyclophosphamide,
cisplatin and BCNU. The relapse-free survival of these
patients appears to be markedly improved over that of his-
torical controls, but a high toxic death rate of 12% is distur-
bing, particularly for a treatment strategy designed for the
adjuvant setting.
It is reasonable to assume that the morbidity associated
with prolonged myelosuppression can be substantially
reduced by employing peripheral blood stem cell transplanta-
tion, with its significantly decreased times to neutrophil and
platelet recoveries. In addition, organ toxicity such as inters-
titial pneumonitis and renal function impairment are
notorious sequelae of high doses of BCNU and cisplatin,
respectively, and regimens employing other drugs may well
prove to be less toxic. To explore these issues, we have
initiated a still ongoing randomised phase II study of high-
dose chemotherapy incorporating cyclophosphamide,
thiotepa and carboplatin (CTC) with autologous peripheral
blood progenitor cell support in high-risk breast cancer fol-
lowing four courses of moderate-dose fluorouracil, epidox-
orubicin and cyclophosphamide (FEC). The high-dose CTC
regimen in this study (Rodenhuis et al., 1992) resembles the
STAMP V regimen of Antman (Antman et al., 1992), but
contains twice the dose of carboplatin. The approach
developed in this study had led to a Dutch national ran-
domised phase III study which has recently begun patient
recruitment. Similar studies have been initiated or are being
planned throughout Europe and in the USA.
Here, we report our single-institution experience with the
mobilisation and harvest ofperipheral blood progenitor cells,High-dose adjuvant chemotherapy in breast cancer
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employing moderate-dose chemotherapy with FEC and G-
CSF, and we describe the toxicity and haemopoietic recon-
stitution after high-dose CTC chemotherapy.
Patients and methods
All patients in the Netherlands Cancer Institute who received
or were scheduled to receive high-dose chemotherapy with
autotransplantation in the adjuvant setting for breast cancer
before 1 May 1994 are described in this report. Twenty-five
patients had been randomised to the high-dose treatment arm
of a single-institution trial for patients with apical axillary
lymph node metastases (study A, see Figure 1 for the study
design) and six patients had been randomised to the high-
dose regimen of a Dutch national trial of high-dose
chemotherapy for breast cancer patients with four or more
axillary lymph nodes (study B, see Figure 1 for the study
design).
The clinical studies were approved by the Institutional
Committee with peer-reviewed treatment protocols. Written
informed consent was obtained from all patients according to
institutional guidelines.
Patients
All patients had histologically confirmed stage II-IIIB
adenocarcinoma of the breast with > 4 involved axillary
lymph nodes, but no distant metastases. Their age was under
60 years, and their WHO performance status was 0 or 1.
Staging procedures include radiography of the chest, an ult-
rasound examination of the liver, a bone scan and full
examination of haematological and biochemistry values.
Renal and hepatic functions had to be adequate with a
creatinine clearance of > 60 mlmin-' and a serum bilirubin
of < 251tmol 1'. A white blood cell (WBC) count of
> 4.0 x I091` 1 and a platelet count of > 100 x I091'
were required. Patients were ineligible if they had a history of
prior or concomitant cancer or any disorder that might
interfere with adherence to the intensive regimen (e.g. cardiac
StudyA (apex node positive)
or pulmonary malfunctioning). No prior chemotherapy or
radiotherapy was allowed.
Treatment regimen
The treatment regimen included the administration of four
cycles of FEC chemotherapy, followed by high-dose
chemotherapy with carboplatin, thiotepa and cyclophos-
phamide (CTC) supported by autologous peripheral stem cell
transplantation (PBSC-T), followed by radiation therapy and
hormonal treatment (Figure 1).
FEC chemotherapy All patients were treated with four 21-
day out-patient cycles of FEC chemotherapy, each cycle
consisting of an escalated dose of epidoxorubicin, i.e.
90mg m-2 (Figure 1, study B) or 120 mg m-2 (Figure 1,
study A), and standard doses of fluorouracil and cyclophos-
phamide, i.e. 500mgm2 each, all administered by i.v. push
(van der Wail et al., 1993).
Central venous access Before the peripheral stem cell
mobilisation procedure, a silicone Hickman double-lumen
catheter (13.5 French) was inserted percutaneously in the
subclavian vein under fluoroscopic control and tunnelled sub-
cutaneously. This procedure was performed in the operating
theatre under strict aseptic conditions. Antibiotic prophylac-
tic treatment consisted of flucloxacillin 4 x 500 mg, starting
just after the insertion of the catheter. If infection or throm-
botic complications required the untimely removal of the
Hickman catheter, leucocytopheresis was performed using a
similar catheter temporarily inserted in the femoral vein.
High-dose chemotherapy was then administered through a
smaller sized, untunnelled catheter in the contralateral sub-
clavian vein.
Stem cell mobilisation and harvest The methods used for the
mobilisation and the harvest ofhaemopoietic progenitor cells
have been described in detail elsewhere (van der Wall et al.,
1994). Briefly, mobilisation of peripheral stem cells was
induced by priming with one course of FEC chemotherapy
Study B (>3 lymph nodes)
FEC x 5
CTC
Tamoxifen I Tamoxifen
Figure 1 Study designs of the two treatment regimens. FEC, fluorouracil, epirubicin, cyclophosphamide; CTC, high-dose
chemotherapy with carboplatin, thiotepa and cyclophosphamide and autologous peripheral progenitor cell transplantation; RT,
radiation therapy; R, randomisation.on day 0, followed by the subcutaneous administration of
300 ig of G-CSF (Filgrastim; Neupogen, Amgen, Thousand
Oaks, CA, USA) for a period of 10 days starting on day 1.
From the seventh day of G-CSF administration, the WBC
count and the percentage of CD34+ mononuclear cells in the
peripheral blood were determined daily. As soon as the WBC
count exceeded 3.0 x 109 1-1 and an unequivocal rise in
CD34+ cell percentage was observed, out-patient
leucocytophereses procedures were started. The
leucocytophereses were performed using a continuous flow
blood cell separator (Fenwal CS 3000, Baxter Deutschland,
Germany). Of the stem cell harvest, the number of CD34+
cells was determined and, in case an unexpected delay in
bone marrow recovery following PBSC-T was observed, the
number of granulocyte-macrophage colony-forming units
(GM-CFU) was determined as well (van der Wall et al.,
1994). A number of > 3.0 x 106 kg-1 CD34+ cells was con-
sidered sufficient for transplantation (van der Wall et al., in
press).
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because of an insufficient rise of CD34+ cells after FEC
mobilisation chemotherapy and G-CSF (see below). The
remaining 28 patients underwent high-dose CTC
chemotherapy and autotransplantation. The characteristics of
these patients are shown in Table I.
PBSC mobilisation
A median number of 10.2 x 106 kg-1 CD34+ cells (range
0.7-25.1), 110 x 104 kg- GM-CFUS (range 9-419) and
3.5 x 10 kg-1 mononuclear cells (MNCs) (range 2.1-12.6)
were harvested, requiring two (median, range 1-4)
haemapheresis sessions (Table II, Figure 2).
In all patients except one, adequate numbers of CD34+
cells, defined as > 3.0 x 106 kg-' in case of PBSC-T without
autologous bone marrow transplantation (ABMT), could be
harvested. In the patient in whom mobilisation was unsuc-
High-dose CTC chemotherapy The high dose chemotherapy
regimen was divided over four consecutive days (day -6 to
day -2) and included cyclophosphamide 1500 mg m-2 day-1
administered as a 1 h intravenous infusion together with a
continuous infusion of 3 g of mesna per day, thiotepa
120 mg m-2 day-' divided over two doses, each as a 1 h
intravenous infusion, and carboplatin 400 mg m 2 day
given as a 2 h infusion (Rodenhuis et al., 1992).
Reinfusion of autologous peripheral blood stem cells took
place on day 0. In 18 of 28 patients, 300 jig of G-CSF
(Neupogen, received as a gift from Amgen-Roche, Breda,
The Netherlands) was administered from the day of rein-
fusion until the WBC count in the peripheral blood exceeded
5.0 x 101-'. Ten consecutive patients did not receive a
haemopoietic growth factor after stem cell reinfusion.
Supportive care During high-dose chemotherapy, patients
were nursed in private rooms without other isolation
measures. Prophylactic antibiotic therapy (selective bowel
decontamination) consisted of oral ciprofloxacin
(500 mg b.i.d) and amphotericin B (500 mg q.i.d) starting 4
days before the start of the CTC regimen. This was supp-
lemented with intravenous penicillin (1 x 106 IU q.i.d.) from
day -2 on and a 6 h intravenous administration of
amphotericin B (0.25 mg kg- ), from day 0 on. The
amphotericin B was routinely administered during the night,
and served as a prophylaxis for fungal infections, including
aspergillosis. Patients who tested positive for anti-Herpes
simplex antibodies received acyclovir prophylactically in a
dose of 400 mg b.i.d. orally or 750 mg daily divided over
three infusions. Three times weekly, cultures from blood,
throat, urine and faeces were taken. In case of a rise in
temperature above 38°C, neutropenic patients were
empirically treated with vancomycin and ceftazidime until
culture results were obtained.
Transfusions of irradiated leucocyte-free red blood cells
were given when the haemoglobin level fell below
5.5 mmol 1-'. In case a low platelet number induced
haemorrhagic diathesis or when platelets were < 10 x 1091`,
transfusions of 5-6 donor units of irradiated platelets were
administered.
Statistics
Differences in haemopoietic recovery were calculated using
the log-rank test. P-values below 0.05 were considered
significant.
Results
From November 1991 until December 1993, 31 patients were
randomised to receive high-dose CTC chemotherapy with
PBSC-T. After randomisation, two patients refused auto-
transplantation. A third patient was taken off protocol
Table I Patient characteristics
No. of patients 31
Not transplanted 3
Refusal 2
PBSC harvest failure 1
Transplanted 28
Median age (range) 44 (25-57)
WHO performance status
0 25
1 3
Study protocol (Figure 1)
A 22
B 6
Bone marrow support
PBSC-T alone 24
PBSC-T + ABMT 4
PBSC, peripheral blood stem cell; PBSC-T, PBSC transplantation;
ABMT, autologous bone marrow transplantation.
Table II Haemopoietic recovery and reinfusion data
Median Range
Day granulocytes> 500 x 106 1-1 16 11-28
No G-CSF after PBSC-T (n = 10)
G-CSF after PBSC-T (n = 18) 9 8-10
Day platelet>, 20 x IO' 1` 12 7-28
No. of RBC units transfused 4 2-8
No. of platelet transfusions 3.5 2-8
CD34+ cells (x 106 kg-') 10.2 0.7-25.1
GM-CFUs (x 104kg-') 109 9-419
MNCs (x 108kg-') 3.55 2.1-12.6
RBC, red blood cell; GM-CFU, colony-forming unit of
granulocytes and macrophages; MNC, mononuclear cell; G-CSF,
granulocyte colony-stimulating factor; PBSC-T, peripheral blood
stem cell transplantation.
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cessful, repeated leucocytopheresis procedures failed to
harvest haemopoietic progenitor cells. Microscopic examina-
tion of a bone marrow specimen showed hypocellularity in
the absence of myelodysplastic features. Cytogenetic analysis
was unremarkable. The first four patients underwent PBSC-T
combined with autologous bone marrow reinfusion, while the
other 24 patients received PBSC-T alone.
Bone marrow recovery
The main toxicity of CTC chemotherapy consisted in bone
marrow suppression (Table II). All patients had periods of
absolute neutropenia and required platelet and red blood cell
transfusions. In the 18 patients who received G-CSF after
PBSC-T, the granulocyte counts had recovered to at least
500 x 106I'1 within a median of 9 days (range 8-10) vs a
median of 16 days (range 11-28) in the ten patients who did
not receive G-CSF following reinfusion (P = <0.001) (Table
II, Figure 3). The number, median and range of progenitor
cells reinfused, as reflected in the number of CD34+ cells,
GM-CFUs and MNCs, was nearly identical in patients who
did or did not receive G-CSF after PBSC-T (data not
shown). The delayed granulocyte recovery observed in the
patients without G-CSF post transplant confirms recently
published data (Spitzer et al., 1994).
Platelet transfusion independence was achieved within a
median of 10 days (range 7-16) in the patients who received
G-CSF after PBSC-T. Platelet recovery did not significantly
differ between patients who received or did not receive G-
CSF: a median of 12 days (range 7-28) was required (Table
II).
Infectious complications
During the neutropenic phase following autotransplantation,
27 patients (96%) developed fever > 38°C, and in 14 ofthese
the origin of the fever could be identified. In four patients,
the fever was accompanied by positive blood cultures for
S taphylococcus epidermidis; in two patients blood cultures
revealed S. aureus, and in another one a Bacillus species was
cultured from the blood (see below). In one patient, an
adenovirus was cultured from a bronchial washing. In four
patients, chest radiographs suggested pulmonary infiltration;
in only one of these was a positive culture obtained from the
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Figure 3 Time to granulocyte recovery (500 x 1061-), with
(solid line) or without (dotted line) the use of G-CSF after
PBSC-T.
sputum. Herpes zoster was encountered once. In one patient,
fever was thought to originate from multiple pulmonary
emboli which occurred in the absence of apparent thrombosis
or cardiac valve abnormalities. Positive blood cultures of
Gram-negative or fungal organisms were not observed.
Thirteen patients (46%) developed fever without an indica-
tion of an infectious origin. They were empirically treated
with vancomycin, 500 mg q.i.d, and ceftazidime, 2 g three
times daily until granulocyte recovery (> 500 x 106 [-1).
Despite the significantly faster granulocyte recovery in
patients who received G-CSF after PBSC-T, the percentage
of patients developing temperature > 38°C and the duration
of fever did not differ when compared with patients who did
not receive G-CSF after reinfusion. However, the duration of
hospitalisation was significantly shortened by the use of G-
CSF post transplant: 14 days (median; range 10-20) in
patients who received G-CSF compared with 17 days
(median; range 13-26) in those who did not (P = <0.001)
(data not shown).
Organ toxicity
During CTC chemotherapy, all patients experienced nausea
and vomiting for a median period of 11 days (range 5-28)
(Table III), resulting in a median weight loss of 3 kg
(range + 2.5 to -9 kg). Three patients received total
parenteral nutrition, starting after PBSC-T, because of a
>5% loss of pretransplant weight.
Mucositis was usually mild; WHO grade 3 was observed in
only 21% of patients. Twenty patients (71%) developed a
skin rash which generally coincided with the empiric adminis-
tration of broad-spectrum antibiotics and which resolved
with their discontinuation (Table III).
Cardiac failure associated with the administration of high-
dose cyclophosphamide was not observed. One patient
developed multiple pulmonary emboli for which she received
conventional treatment with heparin and coumarin
derivatives. None of the patients complained of tinnitus or
hearing loss, but audiograms were not routinely obtained.
Peripheral neuropathy was not encountered.
Biochemical analysis showed brief and reversible elevations
of liver function tests, mainly transaminases and gamma-
glutamyltransferase (y-GT) with maximum values of twice
the upper limit of normal, usually peaking on day 0 (trans-
aminases) and day 9 (T-GT). Renal function was undis-
turbed.
Catheter-related complications
In 18 patients (64%), Hickman-catheter related complica-
tions were observed (Table IV). In 13 patients (46%), cul-
tures of blood drawn from the catheter yielded Gram-
positive organisms, occurring in five patients within 48 h of
catheter implantation. Infection at the entry site or along the
subcutaneous tunnel of the catheter was not observed. No
catheter had to be removed because of infection.
Catheter-induced major vein thrombosis, requiring
removal of the Hickman, occurred in five patients (18%)
(Table IV). In two patients, thrombosis developed 24 h and 1
week after implantation of the Hickman catheter. In these
patients, peripheral stem cells were successfully harvested
using a similar catheter inserted in the femoral vein; high-
dose chemotherapy was later administered through a small
double-lumen catheter, not subcutaneously tunnelled, using
the unaffected contralateral subclavian vein. In one of these
Table HI Non-haematological toxicity (n = 28)
WHO grade duration (days) start (day)a
n median (range) median (range) median (range)
Nausea/vomiting 28 3 (2-4) 11 (5-28) -4 (-6--2)
Diarrhoea 26 3 (2-3) 8 (3-19) 2 (-5-10)
Mucositis 28 2 (1-3) 5 (3-13) 3 (1-10)
Rash 20 2 (1-2) 7 (1-11) 8 (0-11)
aPBSC-T on day 0. PBSC-T, peripheral blood stem cell transplantation.Table IV Catheter-related complications
No. of
patients No. of events
Infectiona 13 17
Major vein thrombosis 5 6
Flow obstruction requiring
streptokinase (see text) 10 10
Untimely removal 5 6
aDefined as positive culture of blood withdrawn from the catheter.
patients, a recurrent thrombotic complication required
removal of the second catheter as well, and a third catheter
was inserted in the femoral vein. In the other three patients,
thrombosis required removal of the catheter 2 and 3 weeks
before and on day 15 after PBSC-T.
In ten patients (36%), backflow obstruction of the catheter
occurred, leading to the inability to withdraw blood from at
least one of the catheter lumina. Patency could be regained in
all cases by a 12-24 h infusion of streptokinase, in a dose of
1000 U per lumen per hour (Table IV). This low-dose
fibrinolytic therapy was effective and uncomplicated despite
platelet transfusion dependence in one of these patients.
The only reason to remove Hickman catheters before the
end of treatment was symptomatic major vein thrombosis
(five cases) (Table IV). Fracture of the Hickman catheter or
spontaneous migration requiring removal did not occur.
Discussion
In 29 young and chemotherapy-naive patients with high-risk
breast cancer, peripheral blood progenitor cells were
mobilised using G-CSF and moderate doses of chemo-
therapy, and 28 of these subsequently underwent high-dose
chemotherapy followed by peripheral stem cell transplanta-
tion. Stem cell mobilisation was successful in all but one of
the patients and typically required only two or three
leucocytopheresis sessions. The high-dose regimen was
reasonably well tolerated, and life-threatening toxicity did
not occur. All transplanted patients had rapid engraftment
with a median time to neutrophil recovery (neutrophils >
0.5 x 109I-l) of 9 days in patients who received G-CSF
following reinfusion (Table II, Figure 3) and a median time
to platelet transfusion independence of 10 days. Despite the
carboplatin dose in this CTC regimen, which is twice as high
as that employed in the STAMP V regimen of the Boston
group (Antman et al., 1992), no renal function impairment
was observed and no symptomatic hearing loss or
neuropathy was reported by the patients. Hepatic toxicity,
which precluded further carboplatin dose escalation in the
Boston phase I study of CTCb (Eder et al., 1990), was
limited to minor elevations of alanine (ALAT) and aspartate
aminotransferases (ASAT), which had usually resolved by the
second day after stem cell reinfusion. In addition, no conges-
tive heart failure associated with high-dose cyclophosphamide
was observed in this patient group.
In our experience, CTC is a high-dose regimen with little
or no severe extramedullary toxicity. We have shown that the
same regimen can be administered twice in a tandem trans-
plantation strategy for the salvage treatment of germ cell
cancer (Rodenhuis et al., 1994). Even then, organ toxicity is
relatively minor, although high-frequency hearing loss and
increase in severity of pre-existent cisplatin neuropathy were
common in these heavily pretreated patients. The conclusion
that CTC is a safe regimen for adjuvant chemotherapy
studies in breast cancer appears to be justified.
Although life-threatening toxicity of CTC was absent and
the time to haemopoietic reconstitution was brief (particular-
ly when G-CSF was used after stem cell reinfusion), the
reversible non-life threatening toxicity was considerable.
Nausea, vomiting and diarrhoea were substantial and occur-
red in almost all patients despite high doses of antiemetics
High-dose adjuvant chemotherapy in breast cancer
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and antidiarrhoeal agents (Table III). Neutropenic fevers
were common, occurring in all but one patient. Skin rashes
of uncertain origin were observed in 71% of the patients,
some of which may have resulted from allergies to antimicro-
bial agents and some of which may have represented skin
toxicity of thiotepa (Wolff et al., 1990). Recent reports in the
news media, suggesting that high-dose chemotherapy for
breast cancer could be administered in an out-patient setting
with patients reporting daily to the transplantation clinic,
clearly apply to either less toxic chemotherapy regimens or to
a small subset of patients. Most of our patients required
hospitalisation from the start of chemotherapy until approxi-
mately 2 weeks after the stem cell reinfusion.
The stem cell mobilisation strategy employed was con-
venient and efficient. The standard chemotherapy designed
for efficacy in breast cancer could very well serve as a
mobilising regimen and the low dose of G-CSF (300fig total
dose irrespective of body weight, as opposed to 10iLg kg-"as
recommended by most authors) led to high peripheral
CD34+ cell counts that allowed the harvest of sufficient
numbers of stem cells in three or fewer leucocytopheresis
sessions in 26 of 29 patients (Figure 2). In only one patient
was no mobilisation at all observed. No cause of this failure
could be identified: the bone marrow was hypocellular but
showed normal morphology, and cytogenetic abnormalities
were absent, arguing against the possibility of a myelodys-
plastic syndrome. The patient was taken off study and an
autologous bone marrow transplantation was not attemp-
ted.
The clinically most important problem of the peripheral
stem cell harvests consisted of complications related to the
indwelling intravenous catheter. Sixty four per cent of all
patients presented with catheter problems on one or more
occasions during the course of their adjuvant treatment. The
most serious problem was major vein thrombosis, which
almost invariably appeared to originate from the subclavian
vein, into which the large-bore silicone Hickman catheter had
been inserted. We have previously reported significant
haemorrhagic complications when attempting to dissolve the
thrombosis employing systemic lose-dose fibrinolysis with
recombinant tissue plasminogen activator while leaving cen-
tral venous catheters in situ (Rodenhuis et al., 1993). As a
result, it was our policy to promptly remove the catheter and
to start the patients on intravenous heparin.
The relatively high frequency ofcatheter-associated venous
thrombosis may be the result of the large-bore catheters that
are being used to facilitate the high blood flow required for
efficient leucocytopheresis sessions (Haire et al., 1990). Since
the large majority of the patients required only 2-3 days of
aphereses and four of five thrombotic events occurred one to
several weeks after the insertion of the catheter, it may be
prudent routinely to insert the catheter immediately before
the first stem cell harvest, and to remove it immediately after
completion of harvesting. A second but smaller and possibly
less thrombogenic central venous catheter could be inserted
later, preferably just before the start of high-dose
chemotherapy.
High-dose chemotherapy with peripheral blood progenitor
cell transplantation is clearly developing into a practical and
safe modality in the adjuvant treatment of breast cancer. It
continues, however, to be associated with substantial reversi-
ble toxicity, requiring prolonged hospitalisation and intensive
supportive care. It can only be employed at considerable
cost, in terms of both loss of well-being of the patient and
her family and cost to society. Whether or not these costs are
justified depends on the presence of a survival benefit which
can only be studied through prospective randomised trials,
some of which are now in progress in Europe and in the
USA.
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